|
|
Achieving SVR Does Not Prevent From Fibrosis Progression In Patients With FCH: Results From A Large French Prospective Multicentric ANRS CO23 Cupilt Cohort
Mylene Sebagh
,
Claire Fougerou-Leurent
,
Georges-Philippe Pageaux
,
Vincent Leroy
,
Jerome Dumortier
et al.
Hepatology, 2017, 66, pp.872A-872A
Journal articles
hal-01684629v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Achieving SVR Does Not Prevent From Fibrosis Progession In Patients With FCH Results From A Large French Prospective Multicentric ANRS CO23 Cupilt Cohort
Mylene Sebagh
,
Claire Fougerou-Leurent
,
Georges-Philippe Pageaux
,
Vincent Leroy
,
Jerome Dumortier
et al.
Hepatology, 2017, 66, pp.872A-872A
Journal articles
hal-01769633v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
EFFICACY AND SAFETY OF TREATMENT WITH BULEVIRTIDE IN CHRONIC HEPATITIS DELTA: PRELIMINARY RESULTS OF THE REAL LIFE ANRS HD EP01 BULEDELTA COHORT
Fabien Zoulim
,
Claire Fougerou
,
Roulot Marullo Dominique
,
Sophie Metivier
,
Victor de Ledinghen
et al.
Hepatology, 2022, 76 (Supp 1), pp.S221-S223
Journal articles
hal-03922586v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation results from the CO23 ANRS CUPILT study
Jerome Dumortier
,
V. Leroy
,
C. Duvoux
,
V. De Lédinghen
,
C. Francoz
et al.
Journal articles
hal-01397762v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation
Pauline Houssel-Debry
,
Audrey Coilly
,
Claire Fougerou-Leurent
,
Caroline Jezequel
,
Christophe Duvoux
et al.
Journal articles
hal-01807755v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|